An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease

Trial Profile

An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Flortaucipir F 18 (Primary) ; Florbetapir F 18
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Diagnostic use
  • Sponsors Avid Radiopharmaceuticals
  • Most Recent Events

    • 04 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
    • 31 Aug 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top